ArticleJournal of medical case reports2025
Probable chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids syndrome: management with corticosteroids and intravenous immunoglobulin-a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Rare brainstem involvement in anti-metabotropic glutamate receptor 1 encephalitis.Frontiers in immunology · 2026Article
- Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).Medical sciences (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids is a rare, subacute inflammatory disorder of the central nervous system with an unknown etiology. It is characterized by distinct clinical (diplopia, ataxia, dysarthria, and altered facial sensation), radiological (punctiform lesions detected on magnetic resonance imaging), and histopathological (predominantly perivascular lymphocytic infiltration, mainly affecting the pons and cerebellum) features. The condition typically demonstrates a favorable response to corticosteroid therapy. CASE PRESENTATION: We report the case of a 54-year-old Caucasian European male who presented with clinical and radiological findings consistent with chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. The patient attended the emergency department at his referral hospital following a 1-month history of progressive neurological symptoms, including diplopia, blurred vision, facial paresis, and gait disturbance attributed to lower limb weakness. Given the clinical presentation and magnetic resonance imaging findings, treatment with oral prednisolone (70 mg/day) was initiated. At 2 weeks post-treatment initiation, the patient exhibited significant clinical improvement, with complete resolution of neurological symptoms. A follow-up brain magnetic resonance imaging scan, performed at the referral center 1 month after starting corticosteroid therapy, demonstrated a reduction in both the size and number of hyperintense lesions in the brainstem on T2-weighted sequences, along with resolution of contrast enhancement. These radiological findings indicated a favorable therapeutic response to chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids treatment. At the 1-month follow-up, the patient remained asymptomatic, leading to a gradual tapering of corticosteroid therapy in light of both clinical and radiological improvement.
conclusionChronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids is a rare neurological disorder that typically presents with ataxic gait, diplopia, and dysarthria. Diagnosis is based on a combination of clinical features, neuroimaging, and histopathology, although brain biopsy is not always feasible. The cornerstone of treatment is immunosuppressive therapy, primarily with corticosteroids, often supplemented with other immunosuppressive agents to prevent relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.